Based on the successful outcome of BRAF inhibitors in other cancers such as cutaneous melanoma, Brastianos et al. used a combination therapy of the RAF inhibitor dabrafenib and MEK inhibitor trametinib in a patient with multiply recurrent BRAFV600E craniopharyngioma [1]. Here, BRAF is linked to cancer.